# Soai University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/soai-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 145 |
| Citations | 4,229 |
| City | Osaka |
| Country | Japan |
| Description | Soai University is a research organisation in Osaka, Japan. OpenAlex records 344 works and 4,229 citations for it. 1 researchers list it as their most recent affiliation. |
| Homepage | https://www.soai.ac.jp/ |
| OpenAlex ID | https://openalex.org/I156498994 |
| Researchers | 1 |
| ROR ID | https://ror.org/059fmyk31 |
| Type | education |
| Works | 344 |

## University papers

Showing 12 of 22.

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update](https://scholariq.org/papers/asia-pacific-clinical-practice-guidelines-on-the-management-of-hepatocellular/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study](https://scholariq.org/papers/global-patterns-of-hepatocellular-carcinoma-management-from-diagnosis-to-death/)
- [NASH limits anti-tumour surveillance in immunotherapy-treated HCC](https://scholariq.org/papers/nash-limits-anti-tumour-surveillance-in-immunotherapy-treated-hcc/)
- [Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma](https://scholariq.org/papers/asian-pacific-association-for-the-study-of-the-liver-consensus-recommendations/)
- [Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012](https://scholariq.org/papers/guidelines-and-good-clinical-practice-recommendations-for-contrast-enhanced-3/)
- [WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 1: Basic Principles and Terminology](https://scholariq.org/papers/wfumb-guidelines-and-recommendations-for-clinical-use-of-ultrasound-elastography-2/)
- [WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver](https://scholariq.org/papers/wfumb-guidelines-and-recommendations-for-clinical-use-of-ultrasound-elastography/)
- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study](https://scholariq.org/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/)
- [Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial](https://scholariq.org/papers/linifanib-versus-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)

## University researchers

- [Masatoshi Kudo](https://scholariq.org/researchers/masatoshi-kudo/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.